Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or upcoming fundraising through debt or equity in the provided transcript. The company has around Rs. 280 crores of unutilized funds, including Rs. 45 crores earmarked for inorganic growth (acquisitions). Management indicated they will continue acquisitions using internal accruals and available funds, suggesting no immediate plans for external fundraising. The focus is on margin improvement and working capital optimization to fund growth internally. No references to new debt or equity issuance were made during the Q&A or management comments.

Any current/future capex/capital investment/strategic investment?

The company has multiple ongoing acquisitions; 9 acquisitions have been completed in FY25, contributing Rs. 750 crores in annualized revenue. Full impact of these acquisitions is expected to reflect from Q3 FY25 onwards, with continued strategic inorganic growth planned. Prabhat Agrawal mentioned pursuing margin-accretive acquisitions, focusing on expanding geography and product categories like specialty pharma, medical devices, diagnostic equipment, and surgical consumables. Rs. 280 crores of unutilized funds (including Rs. 45 crores earmarked for acquisitions) remain available for future acq

Future growth expectations in sales/revenue/volumes?

Targeting 35% revenue growth for the current financial year (FY25), with organic growth at approximately 15% in H1 and expected full-year organic growth at 1.5-2 times the market growth rate (~8% market growth). Inorganic growth to contribute significantly, with completed acquisitions adding Rs. 750 crores in annualized revenue, and total acquisition targets of around Rs. 1,000 crores for FY25 and a similar target planned for FY26. Expect the full impact of acquisitions to be realized primarily in H2 FY25, making second-half numbers lumpy but stronger. Expanding reach covering around 500

Future growth expectations in earnings/operating earnings/profits/EPS?

Guidance for FY25 revenue growth is maintained at 35%-40%. EBITDA margin target of around 4% by end of Q4 FY25, up from 3.3% in Q2 FY25, implying a 70 basis points expansion through a combination of gross margin improvements and operating leverage. Expect consistent quarter-on-quarter margin expansion driven by high-margin acquisitions and operational efficiencies. Profit after tax significantly increased (300% YoY in H1 FY25), reflecting strong margin improvement and optimized finance costs. Operating cash flow expected to turn positive driven by margin expansion and reduction in working capi

Entero Healthcare Solutions LtdQ2 FY25

Entero Healthcare Solutions Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,581.1P/E: 53.3Market Cap: ₹6.9K Cr

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Targeting 35% revenue growth for the current financial year (FY25), with organic growth at approximately 15% in H1 and expected full-year organic growth at 1.5-2 times the market growth rate (~8% market growth).
Inorganic growth to contribute significantly, with completed acquisitions adding Rs. 750 crores in annualized revenue, and total acquisition targets of around Rs. 1,000 crores for FY25 and a similar target planned for FY26.
Expect the full impact of acquisitions to be realized primarily in H2 FY25, making second-half numbers lumpy but stronger.
Expanding reach covering around 500 of 750 districts and increasing retailer coverage from 63,000-65,000 to around 80,000 retailers.
Focus on increasing wallet share and geographical expansion, including new product categories like medical devices, diagnostic equipment, and surgical consumables.
Pursuing margin-accretive acquisitions selectively, with no plans to slow acquisition pace in FY25 and FY26.

Margin guidance

Category 2

Guidance for FY25 revenue growth is maintained at 35%-40%.
EBITDA margin target of around 4% by end of Q4 FY25, up from 3.3% in Q2 FY25, implying a 70 basis points expansion through a combination of gross margin improvements and operating leverage.
Expect consistent quarter-on-quarter margin expansion driven by high-margin acquisitions and operational efficiencies.
Profit after tax significantly increased (300% YoY in H1 FY25), reflecting strong margin improvement and optimized finance costs.
Operating cash flow expected to turn positive driven by margin expansion and reduction in working capital cycle.
Earnings growth supported by both organic growth (~15% in H1 FY25) and inorganic growth via acquisitions.
Acquisition strategy to continue at current intensity, supporting further growth from FY25 onwards.
EPS expected to improve commensurately with EBITDA and PAT growth.

See what Entero Healthcare Solutions Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or upcoming fundraising through debt or equity in the provided transcript.
The company has around Rs. 280 crores of unutilized funds, including Rs. 45 crores earmarked for inorganic growth (acquisitions).
Management indicated they will continue acquisitions using internal accruals and available funds, suggesting no immediate plans for external fundraising.
The focus is on margin improvement and working capital optimization to fund growth internally.
No references to new debt or equity issuance were made during the Q&A or management comments.

Order book

The transcript does not explicitly mention current or expected order book or pending orders details for Entero Healthcare Solutions Limited. However, some relevant points related to future growth and acquisitions include: - The company targets Rs. 1,000 crore worth of acquisitions for FY25 and plans to pursue a similar amount for FY26. - Multiple acquisitions completed in FY25 have contributed to inorganic growth, with more acquisitions expected every quarter. - The full impact of acquisitions done in the first half will reflect in the second half. - Expansion plans include increasing geographic reach and product categories through acquisitions. - The company sees continued opportunities in the market and does not expect the pace of acquisitions to slow down through FY26. - No specific numbers related to order book or pending orders were disclosed in the call.

See what Entero Healthcare Solutions Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company has multiple ongoing acquisitions; 9 acquisitions have been completed in FY25, contributing Rs. 750 crores in annualized revenue.
Full impact of these acquisitions is expected to reflect from Q3 FY25 onwards, with continued strategic inorganic growth planned.
Prabhat Agrawal mentioned pursuing margin-accretive acquisitions, focusing on expanding geography and product categories like specialty pharma, medical devices, diagnostic equipment, and surgical consumables.
Rs. 280 crores of unutilized funds (including Rs. 45 crores earmarked for acquisitions) remain available for future acquisitions.
The acquisition pace is expected to continue through FY25 and FY26, targeting another Rs. 1,000 crores of acquisitions next year.
There are investments in operational efficiencies and talent to integrate acquisitions and prepare for future growth.
HealthEdge platform investment to connect retail pharmacies with warehouses through technology to improve market competition and wallet share.

Track Entero Healthcare Solutions Ltd — get its next earnings analysis in your feed

How does Entero Healthcare Solutions Ltd rank vs peers in ?

Pro feature

ThisEntero Healthcare Solutions Ltd

Rev 2Mar 2

See where Entero Healthcare Solutions Ltd sits in See which companies these are, and every other name in the sector.Open rankings

What Entero Healthcare Solutions Ltd's management said in earlier quarters

Others in Retailing this season

Purple Style Labs Ltd (Q2 FY27)
GMV increased from INR133 crores in Q1 FY26 to INR193 crores in Q1 FY27, indicating strong growth momentum. Key concall takeaways from Purple Style Labs Ltd's…
Rentomojo Ltd (Q2 FY27)
Rentomojo has historically grown at a ~40% CAGR over the past few years, with FY25 to FY26 growth at about 45%, and Q1 FY27 showing nearly 50% YoY growth…
Baazar Style Retail Ltd (Q2 FY27)
Initial subscription to the subsidiary’s share capital is ₹1,00,000 divided into 10,000 equity shares of ₹10 each. Key results statement takeaways from Baazar S
Baazar Style Retail Ltd (Q4 FY26)
Q4FY26 Revenue From Operations: Rs 4,657 Mn, up 35% YoY from Rs 3,452 Mn in Q4FY25 (Pages 6, 7, 15, 16). Key concall takeaways from Baazar Style Retail Ltd's…

Compare:vs Trent Ltd vs Meesho Ltd vs Vedant Fashions Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Entero Healthcare Solutions Ltd Q2 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

Continue your research

What Entero Healthcare Solutions Ltd's management said in earlier quarters

Others in Retailing this season